Czech/SlovakiaCzech RepublicSlovakia

Czech Education Minister Submits Country's First Stem Cell Bill

13.11.2004

Prague - The Czech Minister of Education, Petra Buzkova, has put forward a bill on the scientific and therapeutic use of human embryos and stem cells in mid-October. If approved, the law will allow for extracting human embryonic stem cells (hES) from residual embryos from in vitro fertilization treatments that are damaged or would otherwise be discarded - provided that both parents give their informed consent. Under the terms of the proposed bill scientists will be forbidden to create embryos for obtaining stem cells for research purposes or to clone embryos from stem cells. The bill foresees the establishment of a commission that would authorize research projects with hES. It is envisaged that stem cell research could yield treatments among others for diabetes, Alzheimer's, Parkinson's or cardiovascular diseases.
The Czech Republic currently lacks a regulatory framework for research on human embryonic stem cells and the use thereof (see p. 5). Essential normative standards have been laid down in the European Convention on Human Rights and Biomedicine that precedes statutory legislation in the Czech legal order. “We have 16 centers for assisted reproduction, with hundreds of embryos. We also have good scientific groups ready to start with this research. We hope, that such research will start under very strict regulations,” Vladimir Viklicky, chairman of the Bioethical commission of the Government Council for Research and Development which co-prepared the bill, told EuroBiotechNews. The Christian Democratic Union (KDU-CSL), a party in the governing coalition, strongly opposes the bill for ethical reasons. KDU-CSL First Deputy Chairman Jan Kasal stated in the Prague Post he considers it to be “very disgusting to experiment on human embryos. For me, the frozen or unfrozen embryo has the same value.”
Prof. Petr Dvorak and Dr. Alex Hampl at the Mendel University of Agriculture and Forestry in Brno welcome the new law because “it treats hES in a very similar way as in England. It could change a lot for us, because at present there are serious difficulties to get official financing of hES research.” The law would make it easier to get support from Czech grant agencies and to apply for EU projects, the success of which could be hampered in the light of the unclear legal situation in the Czech Republic. Dvorak and Hampl were the first Czech scientists to isolate hES from surplus embryos (blastocysts) which were donated to them by the Centre for Assisted Reproduction - after the couples and the University's ethical committee gave their consent.
14 cell lines were obtained using mouse embryonic fibroblast feeder layers, but some lines were adapted also to feeders of human fibroblasts. After loosing seven lines due to contamination they could characterize the other seven and have shown in in vitro experiments that they are able to form ecto-, meso- and endodermal cell types. Further in vivo experiments are planned. However due to the lack of financial support Dvorak and Hampl are fearing the closure of their lab at the end of the year. “We are thinking of going abroad, but this is rather theoretical. We will consider all possibilities.”

Czech/SlovakiaCzech RepublicSlovakia

01.02.2010

Prague – After increasing its investment in mid-January, full-service provider CRO FGK Clinical Research GmbH has become a major shareholder in the Czech contract research organization Avemedica s.r.o. Financial details were not...

Czech/SlovakiaCzech RepublicSlovakia

01.02.2010

Pilzen – German antibody drug development and discovery firm Affimed Therapeutics AG (Heidelberg) has spun-out all of its antibody discovery activities into a new Czech subsidiary – AbCheck s.r.o., which is located in Pilzen....

Czech/SlovakiaCzech RepublicSlovakia

18.09.2009

Prague/Jena – German and Czech researchers under Ales Svatos have opened the door to major improvements in the application of high-throughput metabolomics and systematic analyses of small molecules via MALDI-mass spectrometry...

Czech/SlovakiaCzech RepublicSlovakia

19.07.2009

Ceské Budejovice - The scientists from the Biology Centre of the Czech Academy of Science who coordinated the EU project MOBITAG have tabled a report on their attitudes towards political interference in the EU’s GMO authorisation...

Czech/SlovakiaCzech RepublicSlovakia

14.07.2009

Bratislava – According to a new study released by PG Economics, Slovak farmers would benefit more than counterparts in other EU countries from planting genetically-engineered Bt maize. Regional factors, as well as reducing an...

Czech/SlovakiaCzech RepublicSlovakia

14.07.2009

Vestec – The Czech Academy of Sciences and Charles University plan to build a modern biotechnology and biomedicine center, according to reports issued by the Czech Information Agency. With about 40,000 square meters of floor...

Czech/SlovakiaCzech RepublicSlovakia

13.07.2009

Olomouc – A new cluster with a focus on drug development and diagnostics has been established near Palacky University in Olmouc. Called MedChemBio, the centre seeks to attract companies with an interest in medicinal and...

Czech/SlovakiaCzech RepublicSlovakia

12.07.2009

Prague – A biotech company and a pharmaceutical enterprise are the winners of this year’s “Investor of the Year” competition, which is organised by CzechInvest and the country’s Association for Foreign Investment. At the end of...

Czech/SlovakiaCzech RepublicSlovakia

29.04.2009

Prague – A2Z Bio, the Czech subsidiary of UK-based Yorkshire Bioscience, is investing EUR100,000 at the CKD Prague Technological Innovation Centre to launch production of research reagents and services for the biotech R&D market....

Displaying results 11 to 20 out of 70

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-czech-slovakia/browse/1/article/czech-education-minister-submits-countrys-first-stem-cell-bill.html

Image Gallery

Stock list

All quotes

TOP

  • PHARMING (NL)0.53 EUR12.8%
  • BAVARIAN NORDIC (D)14.56 EUR10.3%
  • NICOX (F)2.44 EUR7.5%

FLOP

  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.3%
  • GENFIT (F)22.42 EUR-8.1%
  • DEINOVE (F)12.96 EUR-5.3%

TOP

  • WILEX (D)0.92 EUR61.4%
  • CO.DON (D)3.30 EUR61.0%
  • BIOTECH PHARMACON (N)17.50 NOK59.8%

FLOP

  • CYTOS (CH)0.17 CHF-93.9%
  • BIONOR PHARMA (N)2.11 NOK-47.6%
  • GW PHARMACEUTICALS (UK)219.25 GBP-40.4%

TOP

  • SILENCE THERAPEUTICS (UK)256.00 GBP6221.0%
  • IXICO (UK)71.50 GBP810.8%
  • PHARMING (NL)0.53 EUR783.3%

FLOP

  • CYTOS (CH)0.17 CHF-95.8%
  • EVOCUTIS (UK)0.22 GBP-92.5%
  • AGENNIX (D)0.04 EUR-77.8%

No liability assumed, Date: 18.04.2014

Current issue

All issues

Product of the week

Products

Events

All Events

Partner-Events

München

BioVaria 2014

Frankfurt am Main

7th DVFA Life Science Conference

White Paper